Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods | Zendy

Michael A. Pfaller | Zendy; Naoaki Watanabe | Zendy; Mariana Castanheira | Zendy; S. A. Messer | Zendy; Ronald N. Jones | Zendy

Open Access

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods

Author(s) -

Michael A. Pfaller,

Naoaki Watanabe,

Mariana Castanheira,

S. A. Messer,

Ronald N. Jones

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr342

Subject(s) - broth microdilution , antifungal , microbiology and biotechnology , antimicrobial , clinical microbiology , medicine , antifungal drugs , biology , minimum inhibitory concentration

To compare European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI broth microdilution (BMD) methods for testing the novel antifungal E1210 against a recent collection of 102 clinical isolates of Candida spp.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research